Januvia 50 mg Norway - Norway - Statens legemiddelverk

januvia 50 mg

orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 50 mg

Almogran 12.5 mg Norway - Norway - Statens legemiddelverk

almogran 12.5 mg

almirall, s.a. - almotriptanmalat - tablett, filmdrasjert - 12.5 mg

Hydroxyzine Bluefish 25 mg Norway - Norway - Statens legemiddelverk

hydroxyzine bluefish 25 mg

bluefish pharmaceuticals ab - hydroksyzinhydroklorid - tablett, filmdrasjert - 25 mg

Hydroxyzine Bluefish 10 mg Norway - Norway - Statens legemiddelverk

hydroxyzine bluefish 10 mg

bluefish pharmaceuticals ab - hydroksyzinhydroklorid - tablett, filmdrasjert - 10 mg

Losartan Medical Valley 100 mg Norway - Norway - Statens legemiddelverk

losartan medical valley 100 mg

medical valley invest ab - losartankalium - tablett, filmdrasjert - 100 mg

Losartan Medical Valley 12.5 mg Norway - Norway - Statens legemiddelverk

losartan medical valley 12.5 mg

medical valley invest ab - losartankalium - tablett, filmdrasjert - 12.5 mg

Losartan Medical Valley 50 mg Norway - Norway - Statens legemiddelverk

losartan medical valley 50 mg

medical valley invest ab - losartankalium - tablett, filmdrasjert - 50 mg

Femoston 2 mg / 10 mg Norway - Norway - Statens legemiddelverk

femoston 2 mg / 10 mg

viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 2 mg / 10 mg

Vidaza Kesatuan Eropah - Norway - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Azacitidine Celgene Kesatuan Eropah - Norway - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.